FindTrial
Sign In

Single-arm meta-analysis of EGFR-TKI rechallenge or continue treatment

Single-arm meta-analysis of EGFR-TKI rechallenge or continue treatment - Single-arm meta-analysis of EGFR-TKI rechallenge or continue treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000051189
Enrollment
30
Registered
2023-05-29
Start date
2023-05-29
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EGFR mutated non-small cell lung cancer patients

Interventions

None listed

Sponsors

Department of Respiratory Minami Kyousai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with EGFR-mutation

Exclusion criteria

Exclusion criteria: without rechallenge others

Design outcomes

Primary

MeasureTime frame
continue rate of EGFR-TKI—

Countries

Japan,Asia(except Japan),North America,South America,Australia,Europe,Africa

Contacts

Public ContactFumiiro Kashizaki

Department of Respiratory Minami Kyousai Hospital Department of Respiratory Minami Kyousai Hospital

chibitantan2525@yahoo.co.jp0457822101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026